The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM ...

Heart failure is a global health issue. There is a common notion that heart failures can cause permanent damage and can never ...

Biocardia () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 30% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools ...

New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology ...

Cardiac amyloidosis, once regarded as a rare and elusive cause of heart failure, has rapidly emerged as a critical diagnosis among patients presenting with ...

Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...

Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported late breaking echocardiography results from its Phase ...

AI-enhanced single-shot cine MRI produces superior image quality and provides ventricular measurements comparable to ...

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ...

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases ...

BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 Earnings Call Transcript March 24, 2026 BioCardia, Inc. beats earnings expectations.